샘플 요청 목록

 카트 문의
시장보고서
상품코드
1901507

발열성 호중구 감소증 시장 : 병인별, 치료법별, 위험인자별, 진단 방법별, 국가별, 지역별 - 세계 산업 분석, 규모, 점유율 및 예측(2025-2032년)

Febrile Neutropenia Market, By Etiology, By Treatment, By Risk Factors, By Diagnostic Methods, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032
발행일: | 리서치사: AnalystView Market Insights | 페이지 정보: 영문 355 Pages | 배송안내 : 2-3일 (영업일 기준)

    
    
    




※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

발열성 호중구 감소증 시장 규모는 2024년 107억 8,945만 달러로 평가되었으며, 2025년부터 2032년까지 연평균 복합 성장률(CAGR) 4.2%를 나타낼 전망입니다.

발열성 호중구 감소증은 호중구 수가 비정상적으로 감소한 환자에서 급격하게 발병하는 발열을 말하며, 가장 흔한 원인은 화학요법에 의한 골수억제입니다. 이 상태는 심각한 의료 응급 상황이며 심각한 감염과 패혈증을 예방하기 위해 신속한 항균제 개입이 필요합니다. 종양학의 증례 수가 증가하고 임상가의 위험 계층화 관리 프로토콜이 우선화됨에 따라 세계 시장은 기세를 늘리고 있습니다. 장시간 작용형 G-CSF 제제, 신속 진단 패널, 감염 관리 알고리즘의 진보에 의해 임상 현장에서의 채용에 현저한 변화가 발생하고 있습니다. 그러나 상황은 반드시 밝은 것은 아닙니다. 생물학적 제제의 가격 상승, 항균제 내성, 상환 장벽은 특히 자원이 제한된 환경에서 공정한 접근을 제한하고 있습니다. 그럼에도 불구하고, 정밀한 지지요법 모델, POC(Point of Care) 진단, AI를 활용한 감염 예측 툴이 시험 단계에서 주류로 이행하는 가운데, 이 분야에는 큰 기회가 가득합니다. 이러한 혁신은 발열성 호중구 감소증의 관리를 재정의하고 보다 안전하고 신속하며 비용 효율적인 환자 결과의 기초를 마련하려고 합니다.

발열성 호중구 감소증 시장 역학

세계적으로 증가하는 암 부담

세계보건기구(WHO)에 따르면 세계적으로 증가하는 암 부담이 발열성 호중구 감소증 시장에 있어서 가장 중요한 성장요인입니다. WHO는 노인 증가와 추가적인 위험 요인(예 : 흡연, 비만, 오염)에 대한 노출로 인해 세계 신규 암 사례 수가 미래에 중요한 요소가 될 것이라고 말합니다. 골수억제성 화학요법 및 기타 적극적인 암 치료를 받는 환자 수가 증가함에 따라 호중구 감소증의 발병률이 높아지며, 그 결과 발열성 호중구 감소증의 증례 수도 증가합니다. 데이터에 의하면 화학요법을 받는 환자의 최대 30%에 발열성 호중구 감소증이 인정됩니다. 그 결과, 암 환자수가 계속 증가함에 따라, 발열성 호중구 감소증의 관리 솔루션(예방적 치료나 신속 진단을 포함)의 필요성도 마찬가지로 높아지고 있습니다. 따라서 암 환자수 증가가 발열성 호중구 감소증의 마켓플레이스의 주요 성장요인이 됩니다.

발열성 호중구 감소증 시장 : 세분화 분석

세계의 발열성 호중구 감소증 시장은 병인, 치료법, 위험 인자, 진단 방법, 지역에 따라 세분화됩니다.

병인별로는 그람 음성균, 그람 양성균, 진균 감염, 바이러스 감염으로 분류됩니다. 발열성 호중구 감소증에서 그람 음성균은 높은 병원성과 항생제 내성 증가로부터 이 합병증의 주요한 임상적 원인의 하나로 여겨지고 있습니다. 이들 병원체에는 대장균, 크렙시에라속, 녹농균 등이 포함되어 현재도 주요 원인균으로 꼽히고 있습니다. 미국 질병 예방관리센터(CDC)의 데이터에 의하면, 건강관리 관련 혈류 감염의 40% 이상을 그람 음성균 감염증이 차지하고 있어 면역 기능이 저하된 환자(예 : 암 환자)에 있어서 이러한 감염증의 관리의 중요성을 나타내고 있습니다. 따라서 패혈증으로의 급속한 진행과 이러한 감염으로 인한 사망 위험 증가를 고려하면 광역 스펙트럼 항생제에 의한 즉각적인 개입이 요구됩니다. 장내 세균과 박테리아 유래의 광역 스펙트럼 β-락타마제(ESBL) 생산균의 출현은 이러한 감염의 관리에 더욱 복잡해집니다. 따라서 이러한 미생물 증가를 억제하기 위해 발열성 호중구 감소증(FN) 환경에서의 신규 항생제 개발, 신속한 진단법, 정밀한 항균제 적정 사용 전략의 활용에 대한 수요가 계속 증가하고 있습니다.

치료법별로는 발열성 호중구 감소증(FN)의 치료는 미국 감염증 학회(IDSA) 및 전미 종합암 네트워크(NCCN)의 가이드라인이 나타내는 바와 같이, 발열을 검지하고 나서 60분 이내에 항균제를 개시할 필요가 있기 때문에 거의 완전하게 경험적 항균약 요법에 근거하고 있습니다. 소위 "골든 아워"는 매우 중요하며 FN 환자는 빠르게 패혈증 쇼크에 빠질 수 있습니다. FN 환자의 치료에 주로 사용되는 항생제는 광역 스펙트럼 β-락탐계, 카바페넴계 및 항녹농균계 항생제를 포함합니다. 항균제 내성 증가가 초래하는 세계의 건강 위협에 의해 병원에서는 병용 요법, 광역 스펙트럼 약제, 항균약 적정 사용 프로그램의 도입이 진행되고 있습니다. 이 치료법은 여전히 FN 환자의 치료의 주축이며 즉각적인 정맥 내(IV) 제제와 고감도 병원체 검출 기술의 지속적인 개발과 함께 앞으로도 진화를 계속할 것입니다.

발열성 호중구 감소증 시장 - 지역별 분석

북미의 발열성 호중구 감소증 치료 시장은 고가치이면서 성숙하고 있습니다. 그 이유 중 하나는 이 시장에서 치료되는 암 환자의 비율이 높기 때문입니다. 집중적인 화학요법에 대한 접근이 가능하기 때문에 현재 북미에서는 매우 많은 암 환자가 치료를 받고 있습니다. 게다가 이 지역에서는 많은 암 증례가 기록되어 있어 미국, 캐나다, 멕시코는 2022년의 신규 암 증례 수에 있어서 주요국으로 자리매김했습니다(약 290만건의 신규 사례). 2024년에는 미국에서 약 200만건의 신규 증례가 보고되어 61만 1,000명 이상이 암에 의한 사망을 보고되었습니다. 이들 환자는 골수억제요법을 받고, 대부분은 지지요법으로서 발열성 호중구 감소증(FN) 예방조치를 받고 있기 때문에 발열성 호중구 감소증의 위험이 있는 환자층이 매우 큽니다. 발열성 호중구 감소증(FN) 치료를 위한 확립된 시스템을 갖춘 병원의 정비, 건강관리 종사자에 의한 IDSA(미국 감염증 학회) 및 NCCN(전미 종합암 네트워크)의 FN 관리 가이드라인에 엄격한 준수 뿐만 아니라 G-CSF 바이오시밀러 및 광역 스펙트럼 정맥내 항생제의 급속한 보급으로 발열성 호중구 감소증 환자에 대한 대량의 사례를 관리하고 조기 개입을 실시하고 적극적인 치료를 제공할 수 있게 되었습니다. 미국에서 발열성 호중구 감소증의 치료에 영향을 미치는 요인으로는 항균제 내성 증가 동향, 가치에 기초한 의료 모델의 진전, 응급 및 종양학의 현장에서 신속 분자진단을 활용한 저위험 환자에 대한 위험층별화 경로 및 외래 관리의 보급 등을 들 수 있습니다.

미국의 발열성 호중구 감소증 시장 - 국가별 분석

미국은 북미에서 발열성 호중구 감소증 치료용 의료제품의 최대 시장으로, 세계에서도 유수한 높은 연령조절암 발생률(연간 10만명당 367증례)이 계속 보고되고 있습니다. 많은 환자가 다제 병용 화학요법, 줄기세포 이식, 표적 항암제나 면역요법 처방을 이용한 신규 생물학적 제제/치료를 받는다는 사실로부터 발열성 호중구 감소증을 발병할 위험이 있는 환자가 안정적이고 지속적으로 공급되고 있는 상황입니다. 미국암협회(ACS)의 추계에 따르면 2024년에는 미국에서 약 200만 건의 신규암 사례와 약 61만 1,720건의 암사망이 발생했습니다. 따라서 호중구 감소증(FN) 환자에 대한 예방적 치료, 적절한 경험적/항균 요법 및 고급 지지 요법에 대한 명확한 접근에 대한 매우 강한 수요가 계속되고 있습니다. 위의 장점 외에도 미국 시장에서는 G-CSF 및 고가의 주사제 사용에 대한 건강 보험 회사에 의한 고액의 상환, 패혈증 검출을 위한 자동 경보 시스템의 광범위한 이용, 항균제 적정 사용 프로그램의 적극적인 개발·활용이 진행되고 있습니다. 또한 인종 및 지리적 요인을 기반으로 하는 의료 액세스 격차, 원내 감염 등 비용과 액세스 문제도 존재합니다. 이러한 과제는 외래에서의 FN 관리나 경구 스텝 다운 요법의 도입, 또한 치료 과정의 조기 단계에서 고위험 환자의 선별을 목적으로 한 예측 분석의 도입 등의 혁신과 실용화의 성장 촉진요인이 되고 있습니다.

목차

제1장 발열성 호중구 감소증 시장 개요

  • 분석 범위
  • 시장 추정 연도

제2장 주요 요약

  • 시장 분석
  • 경쟁 인사이트

제3장 발열성 호중구 감소증의 주요 시장 동향

  • 시장 성장 촉진요인
  • 시장 성장 억제요인
  • 시장 기회
  • 시장 전망 동향

제4장 발열성 호중구 감소증 시장 : 산업 분석

  • PEST 분석
  • Porter's Five Forces 분석
  • 시장 성장 전망 : 매핑
  • 규제 체계 분석

제5장 발열성 호중구 감소증 시장 : 높아지는 지정학적 긴장의 영향

  • COVID-19 팬데믹의 영향
  • 러시아·우크라이나 전쟁의 영향
  • 중동 분쟁의 영향

제6장 발열성 호중구 감소증 시장 상황

  • 발열성 호중구 감소증 시장 점유율 분석(2024년)
  • 주요 제조업체별 분석 데이터
    • 기존 기업 분석
    • 신생 기업 분석

제7장 발열성 호중구 감소증 시장 : 병인별

  • 개요
    • 부문별 점유율 분석 : 병인별
    • 그람 음성균
    • 그람 양성균
    • 진균 감염
    • 바이러스 감염

제8장 발열성 호중구 감소증 시장 : 치료법별

  • 개요
    • 부문별 점유율 분석 : 치료법별
    • 경험적 항생제 치료
    • 표적 항생제 치료
    • 지지적 치료

제9장 발열성 호중구 감소증 시장 : 위험 인자별

  • 개요
    • 부문별 점유율 분석 : 위험 인자별
    • 항암제 유발성 호중구 감소증
    • 이식 관련 호중구 감소증
    • 유전적 장애

제10장 발열성 호중구 감소증 시장 : 진단 방법별

  • 개요
    • 부문별 점유율 분석 : 진단 방법별
    • 혈액 배양
    • 영상 검사
    • 골수 천자

제11장 발열성 호중구 감소증 시장 : 지역별

  • 서론
  • 북미
    • 개요
    • 북미의 주요 제조업체
    • 미국
    • 캐나다
  • 유럽
    • 개요
    • 유럽의 주요 제조업체
    • 독일
    • 영국
    • 프랑스
    • 이탈리아
    • 스페인
    • 네덜란드
    • 스웨덴
    • 러시아
    • 폴란드
    • 기타
  • 아시아태평양(APAC)
    • 개요
    • 아시아태평양의 주요 제조업체
    • 중국
    • 인도
    • 일본
    • 한국
    • 호주
    • 인도네시아
    • 태국
    • 필리핀
    • 기타
  • 라틴아메리카(LATAM)
    • 개요
    • 라틴아메리카의 주요 제조업체
    • 브라질
    • 멕시코
    • 아르헨티나
    • 콜롬비아
    • 기타
  • 중동 및 아프리카
    • 개요
    • 중동 및 아프리카의 주요 제조업체
    • 사우디아라비아
    • 아랍에미리트(UAE)
    • 이스라엘
    • 튀르키예
    • 알제리
    • 이집트
    • 기타

제12장 주요 공급업체 분석 : 발열성 호중구 감소증 업계

  • 경쟁 대시보드
    • 경쟁 벤치마킹
    • 경쟁 포지셔닝
  • 기업 프로파일
    • Amneal Pharmaceuticals, Inc.
    • AstraZeneca
    • Aurobindo Pharma Limited
    • Bayer
    • BeyondSpring Inc.
    • Biocon Biologics Ltd.
    • Biogen
    • BristolMyers Squibb
    • Celgene
    • Cellerant Therapeutics, Inc.
    • Coherus BioSciences, Inc.
    • Eli Lilly and Company
    • Fresenius Kabi
    • G1 Therapeutics, Inc.
    • Gedeon Richter Plc.
    • GlaxoSmithKline
    • Hanmi Pharmaceutical Co., Ltd.
    • Intas Pharmaceuticals Ltd.
    • Johnson Johnson
    • Kyowa Kirin Co., Ltd.
    • Merck &Co., Inc.
    • Novartis AG
    • Partner Therapeutics, Inc.
    • Pfizer Inc.
    • Roche
    • Sanofi
    • Spectrum Pharmaceuticals, Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Viatris Inc.
    • Others

제13장 애널리스트의 전방위적 전망

KTH 26.01.19

Febrile Neutropenia Market size was valued at US$ 10,789.45 Million in 2024, expanding at a CAGR of 4.2% from 2025 to 2032.

Febrile neutropenia refers to a rapid-onset fever occurring in patients with abnormally low neutrophil counts, most commonly triggered by chemotherapy-induced bone marrow suppression. This condition represents a high-acuity medical emergency, demanding swift antimicrobial intervention to prevent severe infections and sepsis. The global market is gaining momentum as oncology caseloads rise and clinicians prioritize risk-stratified management protocols. Advancements in long-acting G-CSF formulations, rapid diagnostic panels, and infection-control algorithms are creating measurable shifts in clinical adoption. Yet, the landscape isn't all sunshine-elevated biologic drug prices, antimicrobial resistance, and reimbursement barriers continue to constrain equitable access, especially in resource-limited settings. Even so, the sector is ripe with opportunity as precision supportive-care models, point-of-care diagnostics, and AI-enabled infection-prediction tools move from pilot to mainstream. These innovations are poised to redefine febrile neutropenia management, setting the stage for safer, faster, and more cost-effective patient outcomes.

Febrile Neutropenia Market- Market Dynamics

Rising Global Burden of Cancer

The increasing global cancer burden is the most significant growth catalyst for the febrile neutropenia (FN) market, according to the World Health Organization (WHO), who states that the number of new cancer cases globally is expected to be a significant factor in the future due to increasing numbers of elderly individuals as well as individuals being exposed to additional risk factors (e.g. tobacco use; obesity and pollution). As a larger number of individuals undergo myelosuppressive chemotherapy and/or other types of aggressive cancer treatments, those individuals will experience a rise in incidence of neutropenia which leads to an increase in FN. Data indicates that febrile neutropenia occurs in as many as 30% of patients undergoing chemotherapy. The result is that as the amount of cancer patients continues to grow, the need for FN management solutions (including prophylactic treatments and rapid diagnostics) will grow along with it. Thus, the increase in cancer patient volumes is the main growth driver for the FN marketplace.

Febrile Neutropenia Market- Segmentation Analysis:

The Global Febrile Neutropenia Market is segmented on the basis of Etiology, Treatment, Risk Factors, Diagnostic Methods, and Region.

In terms of etiology, the febrile neutropenia market is divided into gram-negative bacteria, gram-positive bacteria, fungal infections, viral infections. In febrile neutropenia, gram-negative bacteria are considered one of the main clinical causes of this complication because of their high levels of virulence and increasing levels of resistance to antibiotics. Some of these organisms include Escherichia coli, Klebsiella, and Pseudomonas Aeruginosa and they continue to be the primary culprits. Gram-negative infections represent more than 40% of all healthcare-associated bloodstream infections according to data from the Center for Disease Control and Prevention, indicating the importance of managing these infections in patients with compromised immune systems (i.e., oncology patients). Therefore, their rapid advancement into sepsis coupled with an elevated risk of death from these infections warrants an immediate intervention with broad-spectrum antibiotics. The emergence of Beta-lactamase producing Extended Spectrum Beta-Lactamases (ESBLs) from Enterobacterales has added an additional level of complexity to the management of these infections. Therefore, there continues to be an increasing demand for the development of new antibiotics, rapid diagnostics, and the use of precision antimicrobial stewardship strategies in FN settings to help control the rise of these organisms.

Based on treatment, treatment of febrile neutropenia (FN) is almost entirely based on empirical antibiotic therapy because of the need to begin antimicrobials within 60 minutes of detecting fever, as outlined by the Infectious Disease Society of America (IDSA) and National Comprehensive Cancer Network (NCCN) guidelines. The so-called "golden hour" is imperative as FN patients can deteriorate rapidly into septic shock. The principal antibiotics utilized to treat FN patients include broad-spectrum B-lactams, carbapenems and anti-pseudomonal antibiotics. The global health threat posed by the rise in antimicrobial resistance has prompted hospitals to use combination therapy, extended-spectrum agents, and stewardship programs; this segment of care remains the mainstay of treatment for FN patients and will continue to evolve with ongoing developments in the availability of fast-acting intravenous (IV) formulations and high-sensitivity pathogen detection technologies.

Febrile Neutropenia Market- Geographical Insights

The febrile neutropenia treatment market in North America is high-value but mature. One of the reasons for this is because of the high levels of cancer being treated by this market; there's a very large number of cancer patients that are currently being treated in North America due to access to intensive chemotherapy. Additionally, there have been many cancer cases recorded in this geographical area; the United States, Canada, and Mexico have been identified as the leading nations in terms of new cancer cases in 2022 (approximately 2.9 million new cases). It is estimated that in 2024, there will be around 2.0 million new cases reported and over 611,000 deaths reported from cancer in the United States. Because these patients receive myelosuppressive therapies with the majority having supportive FN prophylaxis, there is a large pool of people at risk for febrile neutropenia. Given the establishment of hospitals with well-developed systems for treating FN, the strict adherence by healthcare providers to the IDSA and guidelines of the National Comprehensive Cancer Network (NCCN) for FN management, and the rapid acceptance of G-CSF biosimilars and broad-spectrum IV antibiotics, it is possible to print a high volume of cases, intervene early, and provide aggressive treatment to patients with febrile neutropenia. There are several factors impacting the treatment of febrile neutropenia in the United States, including; the rising trend of increasing antimicrobial resistance, the growing development of value-based care models, and the growing use of risk stratification pathways and outpatient management of FN in lower-risk patients utilizing rapid molecular diagnostics in emergency and oncology settings.

United States Febrile Neutropenia Market- Country Insights

The United States is the largest market in North America for medical products treating febrile neutropenia and continues to have one of the highest age-adjusted rates of cancer incidence (367 cases per 100,000) reported annually in the world. The fact that many patients receive intensive multi-drug chemotherapy, stem cell transplants, and new biologics/treatments with targeted anti-cancer drugs and immunotherapeutic regimens means there is a steady and persistent supply of patients who are at risk for developing febrile neutropenia. The American Cancer Society estimates that there will be approximately 2 million new cases of cancer and approximately 611,720 cancer deaths in the U.S. in 2024. Therefore, there continues to be a very strong demand for clear access to FN prophylactic therapies, appropriate empirical/antimicrobial therapy, and advanced supportive care to patients with FN. In addition to the above-mentioned benefits, the U.S. market is also experiencing high levels of reimbursement provided by health insurance companies for the use of G-CSF and expensive injectable products, as well as broad utilization of automated alert systems for sepsis detection and extensive development and use of antimicrobial stewardship programs. There are also cost and access issues, including disparities in access to care based on race, geographic location, and hospital-acquired infections, which are driving innovation and adoption of the use of outpatient FN management and oral step-down regimens, as well as the introduction of predictive analytics to triage higher-risk patients earlier in the treatment process.

Febrile Neutropenia Market- Competitive Landscape:

The landscape for Febrile Neutropenia is characterized by competition between a number of companies, including Amneal Pharmaceuticals, Inc., AstraZeneca, Aurobindo Pharma Limited, Bayer, BeyondSpring Inc., Biocon Biologics Ltd., Biogen, Bristol Myers Squibb, Celgene Cellerant Therapeutics, Coherus BioSciences, Eli Lilly, Fresenius Kabi, G1 Therapeutics, Gedeon Richter, GSK, Hanmi, Intas Pharmaceuticals, Johnson & Johnson, Kyowa Kirin, Merck & Co., Novartis AG, Partner Therapeutics, Pfizer Inc, Roche, Sanofi, Spectrum Pharmaceuticals, Teva, and Viatris Inc. The competition will primarily be around G-CSFs and G-CSF biosimilars, long acting pegfilgrastim (peg G-CSF or filgrastim) formulations and novel myeloprotective agents that are also part of general oncology portfolios. Biocon Biologics developed and commercialized pegfilgrastim biosimilar Fulphila with Viatris. Fulphila is approved in the U.S., European Union (EU), Canada, and other countries and is intended to decrease the length of time patients with neutropenia are at risk for febrile neutropenia, which provides an opportunity for biosimilars to create both price and access competition. Coherus expanded Pegfilgrastim franchise with UDENYCA and its on-body injection device, before choosing to sell the franchise to Intas/Accord while moving towards focus on Immuno-oncology. BeyondSpring advanced its myeloprotective candidate plinabulin, received Breakthrough Therapy designations for use in chemotherapy related neutropenia, but was ultimately issued an FDA complete response letter requesting additional data. G1 therapeutics' trilaciclib (COSELA) was the first myeloprotective therapy to have received FDA approval for prevention of chemotherapy associated myelosuppression. In this environment, the aforementioned larger pharmaceutical players (Pfizer, Merck, Novartis, Roche, Sanofi, J&J, AstraZeneca, Bayer, Lilly, and Teva) are incorporating FN-risk-reduction approaches into their Immunotherapy and Targeted Therapy regimens, pursuing alliances with biosimilar partners, and utilizing real-world evidence to maintain market shares in both mature and emerging markets, thereby making competition increasingly driven by the need for innovation and access..

Recent Developments:

In August 2025, Intas/Accord announced successful acquisition of UDENYCA, strengthening its biosimilar portfolio and positioning itself as a "global pegfilgrastim supplier." UDENYCA remains indicated to reduce infection incidence (i.e. FN risk) in non-myeloid cancer patients receiving myelosuppressive chemotherapy. The deal transferred not only the product, but also relevant Coherus teams responsible for sales, supply, manufacturing and quality.

In September 2025, Amgen (US) launched a new digital platform aimed at improving patient engagement and adherence to treatment protocols for febrile neutropenia. This initiative reflects Amgen's focus on digital transformation and its recognition of the importance of patient-centric approaches in enhancing treatment outcomes. By leveraging technology, Amgen is likely to strengthen its competitive edge and foster deeper connections with healthcare providers and patients alike.

In August 2025, Roche (CH) announced a significant collaboration with a leading biotechnology firm to develop a novel treatment for febrile neutropenia, which is expected to enter clinical trials in early 2026. This strategic move underscores Roche's commitment to innovation and its proactive approach to addressing unmet medical needs in the oncology space. By aligning with a biotechnology partner, Roche not only enhances its research capabilities but also positions itself to potentially capture a larger market share in the febrile neutropenia segment.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL FEBRILE NEUTROPENIA MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Amneal Pharmaceuticals, Inc.
  • AstraZeneca
  • Aurobindo Pharma Limited
  • Bayer
  • Beyond Spring Inc.
  • Biocon Biologics Ltd.
  • Biogen
  • BristolMyers Squibb
  • Celgene
  • Cellerant Therapeutics, Inc.
  • Coherus BioSciences, Inc.
  • Eli Lilly and Company
  • Fresenius Kabi
  • G1 Therapeutics, Inc.
  • Gedeon Richter Plc.
  • GlaxoSmithKline
  • Hanmi Pharmaceutical Co., Ltd.
  • Intas Pharmaceuticals Ltd.
  • Johnson & Johnson
  • Kyowa Kirin Co., Ltd.
  • Merck & Co., Inc.
  • Novartis AG
  • Partner Therapeutics, Inc.
  • Pfizer Inc.
  • Roche
  • Sanofi
  • Spectrum Pharmaceuticals, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • Others

GLOBAL FEBRILE NEUTROPENIA MARKET, BY ETIOLOGY- MARKET ANALYSIS, 2019 - 2032

  • Gram-Negative Bacteria
  • Gram-Positive Bacteria
  • Fungal Infections
  • Viral Infections

GLOBAL FEBRILE NEUTROPENIA MARKET, BY TREATMENT- MARKET ANALYSIS, 2019 - 2032

  • Empirical Antibiotic Therapy
  • Targeted Antibiotic Therapy
  • Supportive Care

GLOBAL FEBRILE NEUTROPENIA MARKET, BY RISK FACTORS- MARKET ANALYSIS, 2019 - 2032

  • Chemotherapy-Induced Neutropenia
  • Transplant-Related Neutropenia
  • Genetic Disorders

GLOBAL FEBRILE NEUTROPENIA MARKET, BY DIAGNOSTIC METHODS- MARKET ANALYSIS, 2019 - 2032

  • Blood Cultures
  • Imaging Tests
  • Bone Marrow Aspiration

GLOBAL FEBRILE NEUTROPENIA MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • The Netherlands
  • Sweden
  • Russia
  • Poland
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Indonesia
  • Thailand
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Febrile Neutropenia Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Febrile Neutropenia Market Snippet by Etiology
    • 2.1.2. Febrile Neutropenia Market Snippet by Treatment
    • 2.1.3. Febrile Neutropenia Market Snippet by Risk Factors
    • 2.1.4. Febrile Neutropenia Market Snippet by Diagnostic Methods
    • 2.1.5. Febrile Neutropenia Market Snippet by Country
    • 2.1.6. Febrile Neutropenia Market Snippet by Region
  • 2.2. Competitive Insights

3. Febrile Neutropenia Key Market Trends

  • 3.1. Febrile Neutropenia Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Febrile Neutropenia Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Febrile Neutropenia Market Opportunities
  • 3.4. Febrile Neutropenia Market Future Trends

4. Febrile Neutropenia Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Febrile Neutropenia Market: Impact of Escalating Geopolitical Tensions

  • 5.1. Impact of COVID-19 Pandemic
  • 5.2. Impact of Russia-Ukraine War
  • 5.3. Impact of Middle East Conflicts

6. Febrile Neutropenia Market Landscape

  • 6.1. Febrile Neutropenia Market Share Analysis, 2024
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Febrile Neutropenia Market - By Etiology

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Etiology, 2024 & 2032 (%)
    • 7.1.2. Gram-Negative Bacteria
    • 7.1.3. Gram-Positive Bacteria
    • 7.1.4. Fungal Infections
    • 7.1.5. Viral Infections

8. Febrile Neutropenia Market - By Treatment

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Treatment, 2024 & 2032 (%)
    • 8.1.2. Empirical Antibiotic Therapy
    • 8.1.3. Targeted Antibiotic Therapy
    • 8.1.4. Supportive Care

9. Febrile Neutropenia Market - By Risk Factors

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Risk Factors, 2024 & 2032 (%)
    • 9.1.2. Chemotherapy-Induced Neutropenia
    • 9.1.3. Transplant-Related Neutropenia
    • 9.1.4. Genetic Disorders

10. Febrile Neutropenia Market - By Diagnostic Methods

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By Diagnostic Methods, 2024 & 2032 (%)
    • 10.1.2. Blood Cultures
    • 10.1.3. Imaging Tests
    • 10.1.4. Bone Marrow Aspiration

11. Febrile Neutropenia Market- By Geography

  • 11.1. Introduction
    • 11.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
  • 11.2. North America
    • 11.2.1. Overview
    • 11.2.2. Febrile Neutropenia Key Manufacturers in North America
    • 11.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.2.4. North America Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
    • 11.2.5. North America Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
    • 11.2.6. North America Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
    • 11.2.7. North America Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
    • 11.2.8. U.S.
      • 11.2.8.1. Overview
      • 11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.8.3. U.S. Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
      • 11.2.8.4. U.S. Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.2.8.5. U.S. Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
      • 11.2.8.6. U.S. Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
    • 11.2.9. Canada
      • 11.2.9.1. Overview
      • 11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.9.3. Canada Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
      • 11.2.9.4. Canada Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.2.9.5. Canada Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
      • 11.2.9.6. Canada Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
  • 11.3. Europe
    • 11.3.1. Overview
    • 11.3.2. Febrile Neutropenia Key Manufacturers in Europe
    • 11.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.3.4. Europe Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
    • 11.3.5. Europe Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
    • 11.3.6. Europe Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
    • 11.3.7. Europe Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
    • 11.3.8. Germany
      • 11.3.8.1. Overview
      • 11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.8.3. Germany Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
      • 11.3.8.4. Germany Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.3.8.5. Germany Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
      • 11.3.8.6. Germany Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
    • 11.3.9. UK
      • 11.3.9.1. Overview
      • 11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.9.3. UK Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
      • 11.3.9.4. UK Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.3.9.5. UK Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
      • 11.3.9.6. UK Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
    • 11.3.10. France
      • 11.3.10.1. Overview
      • 11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.10.3. France Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
      • 11.3.10.4. France Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.3.10.5. France Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
      • 11.3.10.6. France Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
    • 11.3.11. Italy
      • 11.3.11.1. Overview
      • 11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.11.3. Italy Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
      • 11.3.11.4. Italy Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.3.11.5. Italy Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
      • 11.3.11.6. Italy Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
    • 11.3.12. Spain
      • 11.3.12.1. Overview
      • 11.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.12.3. Spain Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
      • 11.3.12.4. Spain Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.3.12.5. Spain Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
      • 11.3.12.6. Spain Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
    • 11.3.13. The Netherlands
      • 11.3.13.1. Overview
      • 11.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.13.3. The Netherlands Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
      • 11.3.13.4. The Netherlands Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.3.13.5. The Netherlands Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
      • 11.3.13.6. The Netherlands Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
    • 11.3.14. Sweden
      • 11.3.14.1. Overview
      • 11.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.14.3. Sweden Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
      • 11.3.14.4. Sweden Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.3.14.5. Sweden Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
      • 11.3.14.6. Sweden Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
    • 11.3.15. Russia
      • 11.3.15.1. Overview
      • 11.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.15.3. Russia Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
      • 11.3.15.4. Russia Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.3.15.5. Russia Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
      • 11.3.15.6. Russia Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
    • 11.3.16. Poland
      • 11.3.16.1. Overview
      • 11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.16.3. Poland Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
      • 11.3.16.4. Poland Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.3.16.5. Poland Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
      • 11.3.16.6. Poland Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
    • 11.3.17. Rest of Europe
      • 11.3.17.1. Overview
      • 11.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.17.3. Rest of the Europe Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
      • 11.3.17.4. Rest of the Europe Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.3.17.5. Rest of the Europe Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
      • 11.3.17.6. Rest of the Europe Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
  • 11.4. Asia Pacific (APAC)
    • 11.4.1. Overview
    • 11.4.2. Febrile Neutropenia Key Manufacturers in Asia Pacific
    • 11.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.4.4. APAC Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
    • 11.4.5. APAC Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
    • 11.4.6. APAC Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
    • 11.4.7. APAC Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
    • 11.4.8. China
      • 11.4.8.1. Overview
      • 11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.8.3. China Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
      • 11.4.8.4. China Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.4.8.5. China Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
      • 11.4.8.6. China Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
    • 11.4.9. India
      • 11.4.9.1. Overview
      • 11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.9.3. India Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
      • 11.4.9.4. India Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.4.9.5. India Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
      • 11.4.9.6. India Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
    • 11.4.10. Japan
      • 11.4.10.1. Overview
      • 11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.10.3. Japan Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
      • 11.4.10.4. Japan Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.4.10.5. Japan Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
      • 11.4.10.6. Japan Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
    • 11.4.11. South Korea
      • 11.4.11.1. Overview
      • 11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.11.3. South Korea Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
      • 11.4.11.4. South Korea Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.4.11.5. South Korea Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
      • 11.4.11.6. South Korea Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
    • 11.4.12. Australia
      • 11.4.12.1. Overview
      • 11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.12.3. Australia Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
      • 11.4.12.4. Australia Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.4.12.5. Australia Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
      • 11.4.12.6. Australia Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
    • 11.4.13. Indonesia
      • 11.4.13.1. Overview
      • 11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.13.3. Indonesia Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
      • 11.4.13.4. Indonesia Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.4.13.5. Indonesia Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
      • 11.4.13.6. Indonesia Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
    • 11.4.14. Thailand
      • 11.4.14.1. Overview
      • 11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.14.3. Thailand Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
      • 11.4.14.4. Thailand Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.4.14.5. Thailand Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
      • 11.4.14.6. Thailand Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
    • 11.4.15. Philippines
      • 11.4.15.1. Overview
      • 11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.15.3. Philippines Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
      • 11.4.15.4. Philippines Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.4.15.5. Philippines Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
      • 11.4.15.6. Philippines Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
    • 11.4.16. Rest of APAC
      • 11.4.16.1. Overview
      • 11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.16.3. Rest of APAC Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
      • 11.4.16.4. Rest of APAC Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.4.16.5. Rest of APAC Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
      • 11.4.16.6. Rest of APAC Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
  • 11.5. Latin America (LATAM)
    • 11.5.1. Overview
    • 11.5.2. Febrile Neutropenia Key Manufacturers in Latin America
    • 11.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.5.4. LATAM Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
    • 11.5.5. LATAM Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
    • 11.5.6. LATAM Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
    • 11.5.7. LATAM Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
    • 11.5.8. Brazil
      • 11.5.8.1. Overview
      • 11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.8.3. Brazil Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
      • 11.5.8.4. Brazil Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.5.8.5. Brazil Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
      • 11.5.8.6. Brazil Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
    • 11.5.9. Mexico
      • 11.5.9.1. Overview
      • 11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.9.3. Mexico Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
      • 11.5.9.4. Mexico Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.5.9.5. Mexico Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
      • 11.5.9.6. Mexico Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
    • 11.5.10. Argentina
      • 11.5.10.1. Overview
      • 11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.10.3. Argentina Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
      • 11.5.10.4. Argentina Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.5.10.5. Argentina Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
      • 11.5.10.6. Argentina Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
    • 11.5.11. Colombia
      • 11.5.11.1. Overview
      • 11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.11.3. Colombia Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
      • 11.5.11.4. Colombia Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.5.11.5. Colombia Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
      • 11.5.11.6. Colombia Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
    • 11.5.12. Rest of LATAM
      • 11.5.12.1. Overview
      • 11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.12.3. Rest of LATAM Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
      • 11.5.12.4. Rest of LATAM Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.5.12.5. Rest of LATAM Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
      • 11.5.12.6. Rest of LATAM Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
  • 11.6. Middle East and Africa
    • 11.6.1. Overview
    • 11.6.2. Febrile Neutropenia Key Manufacturers in Middle East and Africa
    • 11.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.6.4. Middle East and Africa Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
    • 11.6.5. Middle East and Africa Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
    • 11.6.6. Middle East and Africa Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
    • 11.6.7. Middle East and Africa Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
    • 11.6.8. Saudi Arabia
      • 11.6.8.1. Overview
      • 11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.8.3. Saudi Arabia Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
      • 11.6.8.4. Saudi Arabia Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.6.8.5. Saudi Arabia Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
      • 11.6.8.6. Saudi Arabia Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
    • 11.6.9. United Arab Emirates
      • 11.6.9.1. Overview
      • 11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.9.3. United Arab Emirates Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
      • 11.6.9.4. United Arab Emirates Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.6.9.5. United Arab Emirates Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
      • 11.6.9.6. United Arab Emirates Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
    • 11.6.10. Israel
      • 11.6.10.1. Overview
      • 11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.10.3. Israel Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
      • 11.6.10.4. Israel Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.6.10.5. Israel Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
      • 11.6.10.6. Israel Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
    • 11.6.11. Turkey
      • 11.6.11.1. Overview
      • 11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.11.3. Turkey Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
      • 11.6.11.4. Turkey Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.6.11.5. Turkey Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
      • 11.6.11.6. Turkey Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
    • 11.6.12. Algeria
      • 11.6.12.1. Overview
      • 11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.12.3. Algeria Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
      • 11.6.12.4. Algeria Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.6.12.5. Algeria Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
      • 11.6.12.6. Algeria Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
    • 11.6.13. Egypt
      • 11.6.13.1. Overview
      • 11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.13.3. Egypt Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
      • 11.6.13.4. Egypt Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.6.13.5. Egypt Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
      • 11.6.13.6. Egypt Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
    • 11.6.14. Rest of MEA
      • 11.6.14.1. Overview
      • 11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.14.3. Rest of MEA Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
      • 11.6.14.4. Rest of MEA Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.6.14.5. Rest of MEA Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
      • 11.6.14.6. Rest of MEA Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)

12. Key Vendor Analysis- Febrile Neutropenia Industry

  • 12.1. Competitive Benchmarking
    • 12.1.1. Competitive Dashboard
    • 12.1.2. Competitive Positioning
  • 12.2. Company Profiles
    • 12.2.1. Amneal Pharmaceuticals, Inc.
    • 12.2.2. AstraZeneca
    • 12.2.3. Aurobindo Pharma Limited
    • 12.2.4. Bayer
    • 12.2.5. BeyondSpring Inc.
    • 12.2.6. Biocon Biologics Ltd.
    • 12.2.7. Biogen
    • 12.2.8. BristolMyers Squibb
    • 12.2.9. Celgene
    • 12.2.10. Cellerant Therapeutics, Inc.
    • 12.2.11. Coherus BioSciences, Inc.
    • 12.2.12. Eli Lilly and Company
    • 12.2.13. Fresenius Kabi
    • 12.2.14. G1 Therapeutics, Inc.
    • 12.2.15. Gedeon Richter Plc.
    • 12.2.16. GlaxoSmithKline
    • 12.2.17. Hanmi Pharmaceutical Co., Ltd.
    • 12.2.18. Intas Pharmaceuticals Ltd.
    • 12.2.19. Johnson Johnson
    • 12.2.20. Kyowa Kirin Co., Ltd.
    • 12.2.21. Merck & Co., Inc.
    • 12.2.22. Novartis AG
    • 12.2.23. Partner Therapeutics, Inc.
    • 12.2.24. Pfizer Inc.
    • 12.2.25. Roche
    • 12.2.26. Sanofi
    • 12.2.27. Spectrum Pharmaceuticals, Inc.
    • 12.2.28. Teva Pharmaceutical Industries Ltd.
    • 12.2.29. Viatris Inc.
    • 12.2.30. Others

13. 360 Degree Analyst View

14. Appendix

  • 14.1. Research Methodology
  • 14.2. References
  • 14.3. Abbreviations
  • 14.4. Disclaimer
  • 14.5. Contact Us
샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제